Viking shares surged after its dual-action obesity shot helped patients lose weight and keep it off, even after they cut their dosing schedule in a small, exploratory study
Viking $VKTX says its obesity drug VK2735 maintained up to 97% of prior weight loss with every-other-week dosing and 90% with monthly dosing.
Patients staying on weekly 17.5 mg reached ~22% weight loss by week 33 with no plateau.